Press Releases

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Posted on April 15, 2024

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

Posted on March 26, 2024

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Posted on March 6, 2024

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

Posted on February 21, 2024

INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Posted on February 7, 2024

INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

Posted on January 31, 2024

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Posted on January 22, 2024

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

Posted on January 4, 2024

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

Posted on January 3, 2024

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program

Posted on October 10, 2023

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.